Patient Age and CYP2D6*4/CYP2D6*3 Genotype on Maximal Heart Rate in Patients after Acute Coronary Syndrome Treated with Bisoprolol

被引：0
作者：
V. A. Shumkov
K. A. Zagorodnikova
S. A. Boldueva
A. A. Murzina
V. B. Petrova
机构：
[1] Mechnikov North-Western State Medical University,
来源：
Advances in Gerontology | 2021年 / 11卷
关键词：
beta-blockers; pharmacogenetics; acute coronary syndrome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：362 / 367
页数：5
相关论文
共 50 条
  • [1] Patient Age and CYP2D6*4/CYP2D6*3 Genotype on Maximal Heart Rate in Patients after Acute Coronary Syndrome Treated with Bisoprolol
    Shumkov, V. A.
    Zagorodnikova, K. A.
    Boldueva, S. A.
    Murzina, A. A.
    Petrova, V. B.
    ADVANCES IN GERONTOLOGY, 2021, 11 (04) : 362 - 367
  • [2] Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients
    Okda, Sherouk M.
    El-Bassiouny, Noha A.
    El Amrawy, Ahmed Mahmoud
    Salahuddin, Ahmad
    Elonsy, Sohila M.
    Kassem, Amira B.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (10) : 2539 - 2553
  • [3] Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
    Charoenchokthavee, Wanaporn
    Panomvana, Duangchit
    Sriuranpong, Virote
    Areepium, Nutthada
    BREAST CANCER-TARGETS AND THERAPY, 2016, 8 : 149 - 155
  • [4] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [5] Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity
    Dalton, Rachel
    Lee, Seung-been
    Claw, Katrina G.
    Prasad, Bhagwat
    Phillips, Brian R.
    Shen, Danny D.
    Wong, Lai Hong
    Fade, Mitch
    McDonald, Matthew G.
    Dunham, Maitreya J.
    Fowler, Douglas M.
    Rettie, Allan E.
    Schuetz, Erin
    Thornton, Timothy A.
    Nickerson, Deborah A.
    Gaedigk, Andrea
    Thummel, Kenneth E.
    Woodahl, Erica L.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01): : 147 - 156
  • [6] Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients
    Chan, Sze Wa
    Chu, Tanya T. W.
    Ho, Chung Shun
    Kong, Alice P. S.
    Tomlinson, Brian
    Zeng, Weiwei
    FRONTIERS IN MEDICINE, 2021, 8
  • [7] GenoChip CYP2D6 macroarray as a method to genotype for CYP2D6 variants: results of a validation study in a Caucasian population
    Bank, Paul C. D.
    Swen, Jesse J.
    Guchelaar, Henk-Jan
    van der Straaten, Tahar
    PHARMACOGENOMICS, 2015, 16 (07) : 681 - 687
  • [8] Accurately genotyping CYP2D6: not for the faint of heart
    Nofziger, Charity
    Paulmichl, Markus
    PHARMACOGENOMICS, 2018, 19 (13) : 999 - 1002
  • [9] CYP2D6 polymorphism in patients with eating disorders
    E M Peñas-LLedó
    P Dorado
    Z Agüera
    M Gratacós
    X Estivill
    F Fernández-Aranda
    A LLerena
    The Pharmacogenomics Journal, 2012, 12 : 173 - 175
  • [10] CYP2D6 polymorphism in patients with eating disorders
    Penas-LLedo, E. M.
    Dorado, P.
    Agueera, Z.
    Gratacos, M.
    Estivill, X.
    Fernandez-Aranda, F.
    LLerena, A.
    PHARMACOGENOMICS JOURNAL, 2012, 12 (02) : 173 - 175
12345